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ABSTRACT
Psoriasis is adjudged as prototypic papulosquamous skin condition attributed by the erythematous papules (or) plaques. It occurs at any age but 
commonly seen in age groups of 20–30 and 50–60 years. Psoriasis affects around 2% of the world population. Psoriasis has a broad spectrum of 
skin indications occurring in different forms with common characteristics. It is clinically classified as non-pustular and pustular psoriasis. Existing 
therapies include topical therapy, systematic therapy, and phototherapy. Biological drugs and novel immunological factors have been identified as 
alternative therapy to conventional therapies. These biological drugs show more efficacies with fewer side effects in long-term application.
Keywords: Psoriasis, Biological therapy, Anticytokine therapy, Phototherapy.
INTRODUCTION
Psoriasis is characterized by papulosquamous skin condition with 
erythematous papules (or) plaques. Dysregulation of the immune 
system leads to red, scaly, flaky, chronic inflammatory, and itchy 
patches with increased keratinocytes proliferation [1]. Sometimes, 
the body’s immune system cannot differentiate between the foreign 
particle and its own. During the process of defending itself against 
infection, it may lead to excessive skin cell proliferation. Psoriatic 
arthritis refers to psoriasis that affects the joints. The severity of 
psoriasis varies among individuals of different age groups. Psoriasis 
impacts patient’s psychological stress due to its appearance. This 
stress may trigger psoriasis even more which might worsen the 
condition at times. Psoriasis is prevalent in 2% population around the 
world, mainly seen in the age groups of 20–30 and 50–60 years. Plaque 
psoriasis is prevalent among 80% of individuals, of which around 33% 
suffers from mild diseases and remaining from moderate-to-severe 
conditions [1,2]
TYPES OF PSORIASIS
Psoriasis is classified into a broad spectrum of skin indications. It is 
generally divided into pustular and non-pustular forms. A person can 
represent different forms of psoriasis at the same time. It can affect any 
part of the body. However, all forms show common characteristics like 
erythema with thickened scales, and the size of lesions varies from a 
pinhead to 20-cm diameter. These lesions may appear oval, polycyclic, 
or round in shape [Table 1] [3,4].
Psoriasis vulgaris
About 90% of cases are noticed as psoriasis vulgaris in clinical form. 
It appears as erythematous plaques which are covered by silver 
scales. Lesions distribute symmetrically and frequently occur on the 
knees, scalps, sacral region, and elbow. If psoriatic plaques surface is 
scraped with a blunt scalpel, flakes fall off as layers and it exhibits a 
phenomenon called as “wax spot phenomenon.” Further scrapping 
discloses a wet layer attached to the lesion, and this is the last layer 
of dermal papillae which is referred as “last membrane phenomenon.” 
If it is scraped further, an erythematous background and bleeding foci 
which look like red pinpoints referred as “Woronoff ring” are observed. 
There is no clarified pathogenesis for this ring. However, it may be due 
to a reduced level of prostaglandins in healing lesions [5-8].
Guttate psoriasis
It is mostly seen in children and young adults. The lesions structurally 
look like small droplets and rarely convert into squamous psoriatic 
papules. It usually manifests after a streptococcal infection. It is 
generally linked with HLA-Cw6 gene. These types of psoriasis occur 
on the trunk, proximal part of extremities, scalp, and face. They usually 
revert within 3–4 months, but in rare cases, it develops into plaques [9].
Erythrodermic psoriasis
Nearly 80% of the lesions that affect body surface are categorized as 
a generalized form of psoriasis, plaques, and papules which lose their 
attributes. Desquamation is not so definite, but it causes protein loss as 
well as some systematic problem such as edema of lower extremities, 
and cardiac, hepatic, and renal failure. Damage of skin barrier results 
in systematic reactions, which in turn leads to the development of 
psoriasis vulgaris or erythrodermic psoriasis [10].
Palmoplantar psoriasis
In general, palmoplantar psoriasis occurs on palms, hands, and soles of 
the feet. It affects more on thenar regions than the hypothenar region. 
Usually, erythema does not appear, but incase if it exists, then it appears 
as pinkish yellow lesions. Scales are the main lesions, and thick flakes 
may provide an appearance of keratoderma [11].
Inverse psoriasis
Inverse psoriasis or flexural psoriasis is localized in skin folds. Scaly 
lesions do not form because of friction and moisture produced between 
the skin folds. This form of psoriasis is diagnosed with fissured plaques. 
It is commonly observed in obese individuals with a tendency to 
develop a seborrheic lesion. This type of psoriasis refuses to accept 
classical therapy [10].
Generalized pustular psoriasis
It is the rare form of psoriasis with pustules, usually observed in young 
individuals. It either develops independently or seen as a complication 
of psoriasis vulgaris. In this form, leukocytosis, lymphopenia, and 
nitrogen balance will be increased. Within few days, pustules get dried, 
and new pustules arise within no time. Peripustular erythema has 
behavior to spread which leads to erythrodermia. The disseminated 
region should be promptly treated;otherwise, acute phase may cause 
to the fatal course [10-12].
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Impetigo herpetiform
This type of psoriasis is rarely seen, referred to as generalized pustular 
psoriasis of pregnancy. It contains erythematous lesions with pustules. 
It involves mucous membrane and onycholysis secondary to subungual 
pustules. The lesions cause itching or burning sensation with a foul 
odor. It also shows some additional symptoms such as fever, shivering, 
nausea, and vomiting. It is related with hypocalcemia. Commonly, it 
occurs during subsequent pregnancies.
Localized pustular psoriasis
It is subdivided into two forms as Barber’s-Pustular psoriasis and 
Acrodermatitis continua of hallopeau.
Barber’s-pustular
In general, it is found in women with a family history of palmoplantar 
pustulosis. It is chronic, with 2–4 mm sized pustules which are located 
on the palmoplantar region. Its etiology is merely known. This disease 
is triggered by smoking, tonsillitis, humidity and high temperature.
Acrodermatitis continua of hallopeau
It comes under skin disorder which contains sterile pustular eruption 
located on figures and toes. It involves loss of nails and distal phalanges 
in severe conditions. Pustules join together to form small, polycyclic, 
purulent, fluid-filled vesicles [13].
PSORIATIC ARTHRITIS (PSA)
Its prevalence varies between 5.4 and 7% among patients. Pustular 
psoriasis prevalence ratio rises to 30–40% during psoriatic arthritis 
condition. During the onset of the second or third decade of the life of an 
individual, uncomplicated psoriasis begins and prevalence of psoriatic 
arthritis increases in the third decade. Psoriatic arthritis divided into 
five subgroups by “Moll and Wright” based on clinical form as classical 
PsA, asymmetric oligoarticular arthritis, symmetric polyarticular 
arthritis, arthritis mutilan, and spondylitic form [14,15].
Classical PsA is observed in mere 10% of individuals. It affects distal 
interphalangeal joints of the hands and feet. Asymmetric oligoarticular 
arthritis appears in 11% of cases, and it affects major joints such as 
knee joints and proximal and distal interphalangeal joints. It also 
shows the symmetrical effect on the metacarpophalangeal and 
metatarsophalangeal joints. Symmetric polyarticular form looks similar 
to rheumatoid arthritis, while arthritis mutilan is distinguished by 
progressive osteolysis of phalangeal and metacarpal bones. In general, 
it appears on the hands, but sometimes, its presence can be observed 
on the feet with similar involvement. Spondylitic form is linked with 
peripheral arthritis, where the involvement of spondylitic joints and 
symmetric or asymmetric sacroiliac joint is seen.
PATHOPHYSIOLOGY
Cathelicidin belongs to AMP family in the skin which shows various 
immune regulations. Cathelicidin (LL-37 form) and DNA-complex 
together activates plasmacytoid dendritic cell. During psoriatic 
conditions, human cathelicidin peptide, especially active form of LL-
37, is overproduced and aggregates with self- DNA, which leads to the 
formation of stable complexes. These stable complexes are recognized 
by plasmacytoid dendritic cell through TLR9 in the dermis. Thus, 
activated plasmacytoid dendritic cell releases interferon alpha and 
beta (INF-α and INF-β) which triggers local maturation of myeloid 
dendritic cell. These myeloid dendritic cells activate T-cells which are 
differentiated into T-helper (th1 and th17), which leads to autoreactive 
inflammation in psoriasis [16].
TOPICAL PSORIASIS THERAPY
Corticosteroids
In topical psoriasis treatment, corticosteroid remains a mainstay. Its 
mechanism is not precisely known. It acts as an anti-inflammatory, 
immunosuppressive, and anti-proliferative agent by showing influence 
on gene transcription. Due to its occlusive property, ointments 
are more effective. Its efficacy depends on skin type and plaque 
thickness [17,18]. Fluocinonide (0.005% w/v as solution/foam), 
clobetasol (as 0.005% w/v shampoo/spray), hydrocortisone (1% w/v), 
and betamethasone (0.005% w/v) are most commonly employed active 
agents under this category.
Vitamin D analogs
In the treatment of psoriasis, Vitamin D analogs such as calcitriol, 
calcipotriol, and tacalcitol are involved. In some patients, monotherapy 
of Vitamin D analogs is effective, whereas the combination therapy 
(corticosteroid and Vitamin D analog) shows better efficacy. In the 
United States, calcipotriene was used as topical Vitamin D analog until 
2009, in the form of a cream, ointment, foam, or solution. In Europe, the 
topical Calcitriol ointment is being used, as it shows less irritation when 
compared with calcipotriene [19,20].
Calcipotriene
Calcipotriene is also referred as ,calcipotriol and it is accepted therapy 
for psoriasis. Its mechanism is not precisely known, but it mainly shows 
its efficacy on hyperproliferation of keratinocytes, and it also shows 
efficacy on immune modulation, but it does not show outstanding 
results in psoriasis therapy. Combination therapy (corticosteroid 
and calcipotriene) depicts a rise in clinical response. Combination 
of calcipotriene with betamethasone propionate (0.064%) shows 
more efficacy than monotherapy. Corticosteroid and calcipotriene are 
generally applied twice a day, individually however, a combination of 
these two drugs is administered only once in a day. As calcipotriene 
becomes inactive in the presence of acidic moieties and some 
corticosteroid are acidic in nature, owing to which the data related to 
controlled clinical trial are very sparse to claim the rationale behind 
the usage of combination therapy. However, a combination therapy 
had reasonable approaches when patients used both calcipotriene 
and corticosteroid at different times, once daily. Adverse effects are 
generally minimal a part of skin irritation [21,22].
Calcitriol
Calcitriol mechanism resembles calcipotriene, which shows efficacy on 
hyperproliferation of keratinocytes and inhibits inflammatory mediator. 
In a controlled study, perilesional erythema, perilesional edema, and 
burning sensation were reduced in calcitriol-treated areas [23,24].
Tar
The popularity of psoriasis therapy with tar is now reduced because 
of the availability of some new therapies. Its mechanism is not clearly 
known, but it acts as an antiproliferative agent. Tar can also be used 
with topical corticosteroid. However, it is not commercially available. 
Tar can be used without a prescription and is available in the form of 
shampoo, cream, lotion, oils, ointments, solution, and foam. In general, 
2–3% of tar with 0.1% of triamcinolone cream can be applied twice per 
day to treat plaques. 1% of tar in fatty acid based lotion shows more 
efficacy than 5% conventional tar, and this 1% tar lotion resembles 
calcipotriene, efficacy wise. Tar produces unpleasant odor and it also 
tends to be messy [25,26].
Tazarotene
Tazarotene is safe and effective topical retinoid used in psoriasis 
therapy. 0.1% cream is more effective than 0.05%, but it causes 
some local adverse effects. As absorption of Tazarotene is minimal, 
systemic toxicity is unlikely to even in long-term therapy. Application 
Table 1: Clinical classification of psoriasis
Non-pustular psoriasis Pustular psoriasis
Psoriasis vulgaris Generalized pustular psoriasis
Guttate psoriasis Impetigo herpetiformis
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of tazarotene for 20 min followed by washing causes less irritation 
compared with traditional use [27,28].
Calcineurin inhibitor
0.1% of topical tacrolimus and 1% pimecrolimus have good efficacy 
in treating facial and intertriginous psoriasis, and it is well tolerated 
too. Application of 0.1% pimecrolimus twice a day shows almost 
clearance of lesion. However, when compared to corticosteroids, it is 
less efficacious [29-31].
Anthralin
Since the early 20th century, topical anthralin is used for psoriasis therapy 
and it has good efficacy. Its mechanism of action is not clearly known, but 
it has an anti-inflammatory effect and antiproliferative effect. Adverse 
effects of anthralin are skin irritation and red-brown stains which are 
temporary. The therapy starts with low concentration like 0.1% or 
0.25% for 10–20 min application per day for minimal skin irritation and 
slowly increased until it reaches to contact time of 1 h. Then, slowly, the 
concentration of anthralin is increased on the basis of lesion response 
and tolerance of the patient. In the United States, 1% or 2% cream and 
shampoo of anthralin is commercially available. Application time is 
usually 5–10 min/day, which is gradually increased up to 20–30 min 
depending on the tolerance of patient. The normal skin should not get 
in contact with anthralin as it causes skin irritation. We can protect 
unaffected skin by identifying plaques or by applying petroleum or zinc 
oxide to the unaffected skin before anthralin application [32-34].
PHOTOTHERAPY
Ultraviolet (UV) light
Psoriasis can be controlled using ultraviolet light. It acts as antiproliferative 
and anti-inflammatory agent. For this therapy, taking advice from a 
trained dermatologist is important. According to AAoD, UV-B radiation 
(290–320 nm) can be administered as monotherapy or in combination 
with tar. The inducing dose of UVB for patients should be weekly 3 times. 
Once it achieves remission, maintain the regimen which is recommended 
to prolong the remission [35]. Narrowband UV-B having a range of 311 nm 
is an alternative standard for psoriasis therapy apart from broadband 290 
to 320 nm. Narrowband UV-B dose shows more efficacy than broad brand 
UV-B dose to clear plaque psoriasis and apoptosis [36,37].
UV-A radiation or photochemotherapy (PUVA) warrants strict medical 
supervision. As compared to UV-B, UV-A can go deeper into dermis 
without causing any skin burn. This therapy involves either oral or 
topical (bath) administration of psoralen. If a patient undergoes oral 
therapy, then photosensitizing drug, 8-methoxy-psoralen is injected 
in patient followed with UVA exposure for 2 h. This process happens 
thrice a week until dose increment gets remission. Later, recommended 
dose should be maintained either twice or once weekly. If a patient 
undergoes bath PUVA, then affected area of a patient is soaked for 15–
30 min in psoralen mixed with water before UVA exposure [38].
Photoprotection such as sunscreen, hat, and sun protective goggles is 
used pre- and post-treatment to avoid skin and ophthalmic injuries due 
to the exposure to UV rays. As emollients inhibit UV penetration into the 
skin, it should not be applied to the skin before treatment.
Home phototherapy
Home phototherapy (or) home UV-B is alternative method for office-
based phototherapy. This method should be followed only when 
the clinician suggest it to follow by your own. Excessive use of this 
device should not be practiced, and it should not exceed the number 
of treatment that is prescribed by clinician. To avoid overexposure, 
electronic control is equipped with home phototherapy devices, which 
allows only prescribed numbers of therapies [39].
Excimer laser
Excimer laser at a range of 308 nm produces high energy. This is 
another method with a higher dose of UV-B involvement in the 
treatment of only affected skin. It gives faster results when compared 
with conventional phototherapy. Application of this therapy shows 
erythema and blistering. However, it can be tolerated easily and it 
has not been considered as major side effect by patients. UV-induced 
hyperpigmentation (tanning) is caused by excimer laser, but it can be 
controlled after termination of therapy [40,41].
Saltwater bath
It is proved that natural sunlight with sea water combination can also 
treat psoriasis. Hence, salt water bath with artificial ultraviolet exposure is 
being used for treating psoriasis. Additional factual studies are needed to 
establish the potential of the said therapy for full-fledged application [42].
SYSTEMIC THERAPY
Methotrexate
Since 50 years, folic acid agonist methotrexate is used to treat psoriasis 
and it also shows efficacy for psoriasis arthritis and psoriatic nail disease. 
Initially, its mechanism of action was centered on antiproliferation, but 
later, it was considered as immunosuppressive agent, evidenced by the 
latest studies. It shows efficacy on activated T-cell which helps in the 
treatment of psoriasis. Methotrexate shows less efficacy compared to 
adalimumab. Methotrexate is recommended to be administered once 
weekly through oral, intravenous, intramuscular, or subcutaneous 
routes, and the range of administration is 7.5–25 mg/week [43-45].
Retinoids
Severe psoriasis can be treated with systemic retinoids. It also treats 
pustular and erythrodermic form. HIV-associated psoriasis patients 
also get treated with systemic retinoids. Acitretin is the retinoid used to 
treat psoriasis within the dose range of 25–50 mg/day. Good results are 
seen when acitretin is used in combination with phototherapy. Adverse 
effect associated with retinoids therapy is cheilitis and alopecia [46-49].
Calcineurin inhibitor
Severe instances of psoriasis are treated with cyclosporine, a calcineurin 
inhibitor. It acts as T-cell suppressor and administered in the dose 
range of 3–5 mg/day, orally. Within 4 weeks of treatment, massive 
improvements in patient’s condition can be seen. However, long-term 
use of cyclosporine results in renal toxicity and hypertension [50-52].
Apremilast
Moderate-to-severe plaques are treated with apremilast. It acts as 
phosphodiesterase-4 inhibitor which helps in decreasing the production 
of multiple cytokines which cause psoriasis pathogenesis. The 
therapeutic dose of apremilast is 30 mg twice per day; however, it is 
considered to be less efficacious when compared with cyclosporine, 
ustekinumab, and anti-tumor necrosis factor (TNF) therapies [53-57].
NOVEL THERAPIES
Anti-TNF therapy
TNF-α (a cytokine) induces inflammation in psoriasis by involving 
multiple pathways. It raises adhesion molecules on the vascular 
endothelial cell that facilitates inflammatory cells into lesion. It also 
stimulates keratinocyte of other pro-inflammatory mediators and 
activates dendritic cell and macrophages. Recent studies suggested that 
TNF-α inhibitors play a major role in the treatment of psoriasis [58].
TNF-α gets neutralized by infliximab. As it binds to TNF-α and 
permanently gets it deactivated, it helps in the inhibition of 
inflammatory cytokine production and relieves from the symptoms of 
psoriasis [59,60]. Adalimumab and certolizumab pegol are absolutely 
humanized monoclonal antibodies explored for the management 
of psoriasis, currently available in the market, administered every 
2 weeks. They do exhibit the same mode of action as that of infliximab.
Synthetic receptors such as etanercept have higher empathy for TNF-α 
as compared to natural receptors. This high binding affinity results 
in neutralization of TNF-α-mediated psoriatic inflammation. It can be 
administrated twice a week [61-63].
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Other anticytokine therapy
Pro-inflammatory cytokines are a mediator for various biological 
processes, and it gets stimulated in the body by increasing the level 
of cytokines that lead to many pathologies, autoimmunity, and 
cancer. These anticytokines block the antibodies and neutralize the 
cytokines [64].
Ustekinumab
Dendritic cells produce two interleukin subunits, interleukin (IL)-23 
and IL-12, which play a role in pathology. This Ustekinumab binds to 
IL-23 and IL-12 which inhibits signal transduction pathways and shows 
differences in T-cell as Th1 and Th17. Hence, IL-23 and IL-12 blockage 
leads to reducing the number of Th1 and Th17 in the blood [65].
Apilimod
In myeloid leukocytes synthesis, IL-12 and IL-23 get suppressed 
by Apilimod, which is developed from triazine derivative. Recent 
studies proved that apilimod not only inhibits IL-12 and IL-23 but 
also multidownstream cytokines in the affected skin and increased 
synthesis of IL-10, an anti-inflammatory cytokine [66,67].
Brodalumab
IL-17 plays a major role in the survival of the psoriatic disease. 
Brodalumab acts as human anti-IL-17 receptor which suppresses the 
efficacy of IL-17A, IL-17F, and IL-17A/F [68].
Ixekizumab
Ixekizumab is a novel human monoclonal antibody. IgG4 acts as anti-
IL17 by blocking cytokines, beta-defensins, and antimicrobial peptides 
production in keratinocytes. It also suppresses chemokines which are 
responsible for skin lesions. Moderate-to-severe plaques psoriasis can 
be treated by Ixekizumab [69].
Alefacept
LFA-3, which is expressed on antigen presenting cell, binds to CD2 
molecule and results in the production of mature T-cell and natural 
killer cells. Hence, this LFA-3 with CD2 molecule will produce a signal 
that results to the activation of naïve T-cell in effector cell. Alefacept 
blocks the interaction between CD2 molecule and LFA-3 and, hence, 
prevents T-cell activation and proliferation [70,71].
Small molecule inhibitor
Small molecules inhibitors serve as better alternatives to treat psoriatic 
conditions which remain untreated with conventional therapies. These 
agents assist in inhibiting signaling pathways that help in eliciting 
inflammatory cytokines [72]. Different categories of therapeutic agents 
are being discussed here.
Phosphodiestrase-4 inhibitor
T-cell secretes inflammatory cytokines such as IFN-γ, TNF-α, and IL-
12 from monocytes in blood. Inhibition of phosphodiesterase helps in 
suppressing T-cell secretion [53,73-75].
Protein kinase inhibitor
Protein kinase C inhibition helps to inhibit classical and novel protein 
kinase C which regulates immune signaling cascade and INF-γ and IL-
17 production [75,76]
Mitogen-activated protein kinase inhibitor
Different inflammatory diseases have been chronicled the importance 
of nitrogen-activated protein kinase. It shows involvement in cell 
proliferation, inflammation, and differentiation. p38-MAPK is over 
expressed in psoriatic lesions and BMS582949 is identified as a novel 
selective p38-MAPK inhibitor [77,78].
Janus kinase inhibitor
Several cytokines receptors are connected with Janus kinase which 
belongs to cell-signaling molecules. Janus kinase activates STAT 
pathway which controls the expression of a nuclear target in gene and 
induces pro-inflammatory gene. JAK3 shows involvement in IL-2, IL-6, 
IL-7, IL-15, and IL-21 signaling. Tofacitinib inhibits the JAK1 and JAK3. 
ASP015K4 and VX-509 inhibit JAK3, and INCB28050 inhibits JAK 1 and 
JAK2 [79,80].
Nerve growth factor inhibitor
Large quantities of neuropeptides are released by sensory nerve fiber 
due to stress. Research also proved the link between emotional stress 
and peripheral nervous system, resulting in the onset of psoriasis 
lesion. T-cell activation, keratinocytes proliferation, angiogenesis, and 
cutaneous nerve proliferation have been activated by nerve growth 
factors which are present in psoriatic lesional and non-lesional plaques. 
K252a and CT327 act as NGF inhibitors and available as topical therapy.
OTHER THERAPIES
Insulin
In dermis, IL-1β is present in a large amount which activates P38-MAPK 
(mitogen-activated protein kinase). This kinase acts on insulin receptor 
and induces the insulin resistance in the keratinocytes, which in turn 
alters keratinocytes proliferation and differentiation and subsequent 
alleviation of symptoms related to psoriasis.
Magnetic therapy
The use of magnetic therapy with low frequency for psoriasis therapy 
helps for the treatment of both skin and joint manifestation. Magnetic 
therapy acts as anti-inflammatory for healing, soothing, reducing itch, 
immunostimulator, and detoxification effects. When both active periods 
of skin lesion and remission phase are present, this magnetic therapy is 
used. The affected area is attached with applicator, beneficial to liver and 
stomach therapy by supporting liver detoxification, metabolic function, 
and absorption process and adjusting the digestion. Depending on the 
development and course of disease, application of therapy will be given 
repeatedly (or) throughout sufferer lifetime.
CONCLUSION
Psoriasis is persistent, familial, non-communicable skin disease, with 
no precise cure. A constellation of therapy is available which can control 
the disease of psoriasis among people. Along with existing therapies, 
the novel therapies such as anticytokines, small molecule inhibitor, 
NGF inhibitor, and corticosteroids [81] and other therapies became 
more prevalent in recent years for the treatment of psoriasis. Although 
various therapies and drugs are present in the market, still no drugs can 
permanently cure psoriasis and few of them elicit severe adverse effects. 
Biological drugs and novel immunological factors act as alternatives to 
conventional therapies which give a better understanding for functional 
and immunological pathways of treating psoriasis. These biological 
drugs show more efficacies with fewer side effects even in long-term 
usage. Despite their huge cost, it really offers a better alternate for 
improving the quality of life for patients. Novel drug delivery systems 
are also found to be effective for the treatment of psoriasis [82].
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